Published on 04/12/2025

Potency Assays: Cell-Based vs Binding—Which and Why

Introduction to Potency Assays in Biologics Validation

In the realm of biopharmaceutical development and manufacturing, the validation of potency assays is a critical component, particularly when engaging with advanced therapeutic medicinal products (ATMPs) and biologics. Potency assays serve as key quality control mechanisms to assess a product’s therapeutic efficacy and ensure consistent performance across batches. This tutorial guide explores two predominant types of potency assays: cell-based and binding assays. Both approaches have distinct methodologies, regulatory expectations, and practical applications, which are essential to comprehend for effective validation planning and execution.

Understanding the core principles underpinning these assays—specifically within the framework of viral clearance validation and spiking studies—is essential for professionals in pharmaceuticals, particularly in the context of compliance with regulations set forth by the US FDA, EMA, and other global regulatory bodies.

Understanding Potency Assays: Definitions and Importance

Potency assays are designed to quantify the biological activity of a drug product. These assays are classified primarily into two categories: cell-based potency assays, which evaluate the product’s effect on living cells, and binding assays, which assess the interaction between the drug and its target molecule. A thorough understanding of these assays is vital in formulating a robust validation strategy adhering to guidelines such as ICH Q5A(R2).

The significance of potency assays extends beyond compliance; they are pivotal in determining the quality attributes of biologics. The manner in which potency is tested influences product safety, efficacy, and adherence to regulatory standards. Issues such as variabilities in assay conditions can lead to significant discrepancies in potency determination, thereby impacting clinical outcomes.

Cell-Based Potency Assays: Methodologies and Applications

Cell-based potency assays leverage live cells to evaluate the therapeutic effect of a biologic. This method focuses on the biological response of cells to the product and is particularly relevant for vaccines, monoclonal antibodies, and gene therapies. The primary advantage of cell-based assays lies in their capacity to closely mimic the in vivo environment, thus providing a more accurate representation of a product’s functionality. Below, we outline the key methodologies employed in these assays:

• Assay Design: The design of a cell-based assay should involve an understanding of the target mechanism of action. Factors such as the choice of cell line, the selection of appropriate readouts (e.g., viability, proliferation, signaling), and the establishment of a control system are critical.
• Validation Parameters: Key parameters that need to be established and validated include specificity, sensitivity, reproducibility, and robustness. These factors correlate with the assay’s capability to detect variations in potency accurately.
• Regulatory Compliance: Compliance with applicable regulations, such as those outlined in the ICH guidelines, is crucial in establishing assay validity. Final documentation should reflect adherence to guidelines and standards set by bodies such as the EMA.

As a best practice, developers should prepare for viral clearance validation alongside assay development to mitigate the risk of potential contamination throughout the production process, particularly when utilizing closed systems and single-use systems where cross-contamination is a significant concern.

Binding Assays: Methodologies and Applications

Binding assays, in contrast to their cell-based counterparts, focus on quantifying the interaction between a drug product and its target without requiring living cells. This methodology often employs techniques such as ELISA (enzyme-linked immunosorbent assay), surface plasmon resonance (SPR), and radiolabeled ligand assays. Understanding the operational intricacies of these assays is pivotal for professionals involved in biologics validation.

• Assay Design: Binding assays necessitate careful selection of reagents, such as antibodies or ligands, to ensure high specificity and affinity for the target. The design phase should take into account buffer composition, incubation times, and temperature control.
• Calibration and Standardization: Establishing a robust calibration curve and implementing control systems are essential for ensuring assay accuracy and reliability. Standardization is particularly important in mitigating variabilities between different assay runs.
• Regulatory Compliance: Similar to cell-based assays, binding assays must conform to regulatory expectations. Detailed documentation and validation reports are imperative to demonstrate compliance with guidelines including those from the WHO and other relevant authorities.

Binding assays play a critical role in determining the identity of the biological product, marking their importance in the product development lifecycle. The design must accommodate considerations for spiking studies to evaluate potential cross-reactivity and accuracy of results.

Choosing Between Cell-Based and Binding Assays: Factors to Consider

When determining which type of potency assay to employ, there are several key factors that professionals in the pharmaceutical industry should consider:

• Nature of the Product: The selection should be aligned with the biological function and the complexity of the product. For instance, products with complex mechanisms of action may necessitate the use of cell-based assays to adequately capture their effects.
• Regulatory Guidance: Understanding the applicable regulatory framework is crucial. Regulatory agencies may provide specific recommendations on the preferred type of assay based on product class and intended use.
• Resource Availability: Cell-based assays generally require more extensive resources, including specialized equipment and reagents. Conversely, binding assays may deliver quicker results with fewer resource demands.

A systematic evaluation of these factors will enable organizations to plan and implement an effective validation strategy conducive to maintaining compliance and ensuring product quality.

Validation of Potency Assays: Steps and Best Practices

Implementing a comprehensive validation strategy for potency assays is crucial in complying with regulatory requirements and ensuring product quality. The following outlines a step-by-step approach to validating potency assays:

1. Study Design and Objectives: Define the purpose of the assay and establish study objectives. This should include identifying critical quality attributes (CQAs) pertinent to potency.
2. Method Development: Design the assay protocol based on the chosen assay type (cell-based or binding). Ensure that all reagents, controls, and validation criteria are clearly defined.
3. Perform Preliminary Studies: Conduct initial experiments to assess feasibility and identify any potential issues with the assay’s execution.
4. Stability and Robustness Testing: Test the assay under varying conditions to establish its robustness. This includes evaluating performance under different environmental conditions and sample matrices.
5. Validation Experiments: Carry out an extensive validation study, including specificity, sensitivity, accuracy, precision, repeatability, and reproducibility. Document all findings comprehensively.
6. Final Report and Review: Compile a validation report that includes all experimental data, findings, and conclusions. Review the report in accordance with quality management systems (QMS) to ensure compliance.

In addition to these steps, it is essential to integrate continuous process verification (CPV) into the validation framework to ensure ongoing compliance and assurance of product quality. This is particularly relevant in the context of complex medicinal products like ATMPs.

Conclusion: Aligning Potency Assay Validation with Regulatory Standards

Ultimately, the choice between cell-based and binding assays should be guided by the specific characteristics of the product in question, the regulatory landscape, and the overarching goals of the product development lifecycle. By understanding the nuanced differences in methodology and application, professionals can develop a thorough validation plan that adheres to the stringent requirements put forth by agencies like the FDA and EMA.

As the biopharmaceutical landscape continues to evolve, incorporating a culture of quality and compliance into the potency assay validation process will serve both to enhance product integrity and to support safe and effective therapeutic interventions for patients worldwide.